Mefprex-P Suspension is a combination analgesic and antipyretic formulation containing Mefenamic Acid (50mg/5ml) and Paracetamol (125mg/5ml). It is indicated for the management of mild to moderate pain and fever associated with various conditions such as dental pain, musculoskeletal pain, dysmenorrhea, and post-operative pain. Mefenamic Acid, a non-steroidal anti-inflammatory drug (NSAID), exerts its effect by inhibiting cyclooxygenase enzymes, thereby reducing the synthesis of prostaglandins responsible for inflammation and pain. Paracetamol acts centrally to elevate the pain threshold and reduce fever through inhibition of the hypothalamic heat-regulating center. The combination provides enhanced analgesic efficacy by targeting multiple pain pathways. Mefprex-P Suspension is suitable for pediatric and adult patients requiring liquid dosage forms. The recommended dosage should be adhered to strictly, and treatment duration should be limited to the shortest possible period to minimize adverse effects. Caution is advised in patients with hepatic or renal impairment, peptic ulcer disease, or hypersensitivity to NSAIDs or paracetamol. Common side effects may include gastrointestinal discomfort, nausea, and allergic reactions. Consultation with a healthcare professional is essential before initiating therapy to ensure appropriate use and to prevent potential drug interactions.